SCHEMBL14979889

SCHEMBL14979889

C=CCc1c(OCCCC)c2cc(Br)ccc2[nH]c1=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.41
HTT P42858 1/20 0.41
PRNP P04156 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
PPARG P37231 1/20 0.40
HIF1A Q16665 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
NR2E3 Q9Y5X4 1/20 0.40
NCOR2 Q9Y618 1/20 0.40
HSD17B10 Q99714 6/20 0.40
ALDH1A1 P00352 4/20 0.40
KMT2A Q03164 2/20 0.40
CASP1 P29466 1/20 0.40
CASP7 P55210 1/20 0.40
GSK3B P49841 1/20 0.39
TSHR P16473 1/20 0.38
KDM4E B2RXH2 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14969306 0.81 KMT2A (0.41) MAPTPRNPCYP1A2CYP2C9CYP2C19
SCHEMBL14969206 0.75 ALDH1A1 (0.46) MAPTPRNPCYP1A2CYP2C9CYP2C19
SCHEMBL16662097 0.71 GSK3B (0.48) MAPTPRNPCYP1A2CYP2C9CYP2C19
SCHEMBL12647097 0.71 CHRNB2 (0.56) MAPTPRNPCYP1A2CYP2C9CYP2C19
SCHEMBL7124940 0.68 HSD17B10 (0.45) MAPTHTTPRNPCYP1A2CYP2C9
SCHEMBL29056092 0.67 ATM (0.42) MAPTHTTCYP1A2CYP2C9CYP2C19
SCHEMBL7117408 0.66 ALDH1A1 (0.65) MAPTHTTPRNPCYP1A2CYP2C9
SCHEMBL16651204 0.65 GSK3B (0.47) MAPTPRNPCYP1A2CYP2C9CYP2C19
SCHEMBL31384364 0.64 ALDH1A1 (0.63) MAPTPRNPCYP1A2CYP2C9CYP2C19
SCHEMBL8162707 0.64 RAB9A (0.48) MAPTHTTPRNPCYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9328138-B2 HCV NS3 protease inhibitors MSD ITALIA S.R.L. (IT) 2016-05-03 US disclosed
US-20140296136-A1 HCV NS3 PROTEASE INHIBITORS MERCK SHARP & DOHME LLC 2014-10-02 US disclosed
WO-2013074386-A2 HCV NS3 PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2013-05-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140296136-A1 HCV NS3 PROTEASE INHIBITORS HAVCR2, GTF3C3, CTSC MAPT 4330/4885HTT 3331/4885PRNP 896/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.